A Nontoxic Transduction Enhancer Enables Highly Efficient Lentiviral Transduction of Primary Murine T Cells and Hematopoietic Stem Cells.

Abstract:

:Lentiviral vectors have emerged as an efficient, safe therapeutic tool for gene therapy based on hematopoietic stem cells (HSCs) or T cells. However, the monitoring of transduced cells in preclinical models remains challenging because of the inefficient transduction of murine primary T cells with lentiviral vectors, in contrast to gammaretroviral vectors. The use of this later in preclinical proof of concept is not considered as relevant when a lentiviral vector will be used in a clinical trial. Hence, there is an urgent need to develop an efficient transduction protocol for murine cells with lentiviral vectors. Here, we describe an optimized protocol in which a nontoxic transduction enhancer (Lentiboost) enables the efficient transduction of primary murine T cells with lentiviral vectors. The optimized protocol combines low toxicity and high transduction efficiency. We achieved a high-level transduction of murine CD4+ and CD8+ T cells with a VSV-G-pseudotyped lentiviral vector with no changes in the phenotypes of transduced T cells, which were stable and long-lived in culture. This enhancer also increased the transduction of murine HSCs. Hence, use of this new transduction enhancer overcomes the limitations of lentiviral vectors in preclinical experiments and should facilitate the translation of strategies based on lentiviral vectors from the bench to the clinic.

authors

Delville M,Soheili T,Bellier F,Durand A,Denis A,Lagresle-Peyrou C,Cavazzana M,Andre-Schmutz I,Six E

doi

10.1016/j.omtm.2018.08.002

subject

Has Abstract

pub_date

2018-08-08 00:00:00

pages

341-347

issn

2329-0501

pii

S2329-0501(18)30079-2

journal_volume

10

pub_type

杂志文章
  • Human fetal liver cells for regulated ex vivo erythropoietin gene therapy.

    abstract::Possible risks and lack of donor livers limit application of liver transplantation. Liver cell transplantation is, at this moment, not a feasible alternative because engraftment in the liver is poor. Furthermore, there is also shortage of cells suitable for transplantation. Fetal liver cells are able to proliferate in...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.3

    authors: El Filali E,Duijst S,Hiralall JK,Legrand N,van Gulik T,Hoekstra R,Seppen J

    更新日期:2014-03-12 00:00:00

  • A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications.

    abstract::Surfactant protein B (SPB) deficiency is a severe monogenic interstitial lung disorder that leads to loss of life in infants as a result of alveolar collapse and respiratory distress syndrome. The development and assessment of curative therapies for the deficiency are limited by the general lack of well-characterized ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.11.013

    authors: Munis AM,Hyde SC,Gill DR

    更新日期:2020-11-20 00:00:00

  • Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor.

    abstract::Adoptive natural killer (NK) cell therapy is attaining promising clinical outcomes in recent years, but improvements are needed. Genetic modification of NK cells with a tumor antigen-specific receptor on their surface coupled to intracellular signaling domains may lead to enhanced cytotoxicity against malignant cells....

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.03.017

    authors: Gong Y,Klein Wolterink RGJ,Janssen I,Groot AJ,Bos GMJ,Germeraad WTV

    更新日期:2020-03-29 00:00:00

  • All-in-one processing of heterogeneous human cell grafts for gene and cell therapy.

    abstract::Current cell processing technologies for gene and cell therapies are often slow, expensive, labor intensive and are compromised by high cell losses and poor selectivity thus limiting the efficacy and availability of clinical cell therapies. We employ cell-specific on-demand mechanical intracellular impact from laser p...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.12

    authors: Lukianova-Hleb EY,Yvon ES,Shpall EJ,Lapotko DO

    更新日期:2016-03-16 00:00:00

  • Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes.

    abstract::Osteoarthritis (OA) is a joint disease characterized by degeneration of the articular cartilage, subchondral bone remodeling, and secondary inflammation. It is among the top three causes of chronic disability, and currently there are no treatment options to prevent disease progression. The localized nature of OA makes...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.8

    authors: Ruan MZ,Cerullo V,Cela R,Clarke C,Lundgren-Akerlund E,Barry MA,Lee BH

    更新日期:2016-03-09 00:00:00

  • Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing.

    abstract::The advent of RNA-guided endonuclease (RGEN)-mediated gene editing, specifically via CRISPR/Cas9, has spurred intensive efforts to improve the efficiency of both RGEN delivery and targeted mutagenesis. The major viral vectors in use for delivery of Cas9 and its associated guide RNA, lentiviral and adeno-associated vir...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.57

    authors: Park A,Hong P,Won ST,Thibault PA,Vigant F,Oguntuyo KY,Taft JD,Lee B

    更新日期:2016-08-24 00:00:00

  • Development of Gene Transfer for Induction of Antigen-specific Tolerance.

    abstract::Gene replacement therapies, like organ and cell transplantation are likely to introduce neo-antigens that elicit rejection via humoral and/or effector T cell immune responses. Nonetheless, thanks to an ever growing body of pre-clinical studies it is now well accepted that gene transfer protocols can be specifically de...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.13

    authors: Sack BK,Herzog RW,Terhorst C,Markusic DM

    更新日期:2014-04-30 00:00:00

  • Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

    abstract::The marketing approval of genetically engineered hematopoietic stem cells (HSCs) as the first-line therapy for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a tribute to the substantial progress that has been made regarding HSC engineering in the past decade. Rep...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2017.03.003

    authors: Wang X,Rivière I

    更新日期:2017-03-18 00:00:00

  • Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV.

    abstract::Human immunodeficiency virus (HIV) is an attractive target for chimeric antigen receptor (CAR) therapy. CAR T cells have proved remarkably potent in targeted killing of cancer cells, and we surmised that CAR T cells could prove useful in eradicating HIV-infected cells. Toward this goal, we interrogate several neutrali...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.09.014

    authors: Urak RZ,Soemardy C,Ray R,Li S,Shevchenko G,Scott T,Lim L,Wang X,Morris KV

    更新日期:2020-09-28 00:00:00

  • Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced Ex Vivo and In Vivo Genetic Engineering.

    abstract::Lentiviral vectors (LVs) are increasingly employed in gene and cell therapy. Standard laboratory production of LVs is not easily scalable, and research-grade LVs often contain contaminants that can interfere with downstream applications. Moreover, purified LV production pipelines have been developed mainly for costly,...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.10.009

    authors: Soldi M,Sergi Sergi L,Unali G,Kerzel T,Cuccovillo I,Capasso P,Annoni A,Biffi M,Rancoita PMV,Cantore A,Lombardo A,Naldini L,Squadrito ML,Kajaste-Rudnitski A

    更新日期:2020-10-20 00:00:00

  • A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome.

    abstract::Crigler-Najjar syndrome is a severe metabolic disease of the liver due to a reduced activity of the UDP Glucuronosyltransferase 1A1 (UGT1A1) enzyme. In an effort to translate to the clinic an adeno-associated virus vector mediated liver gene transfer approach to treat Crigler-Najjar syndrome, we developed and optimize...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.49

    authors: Ronzitti G,Bortolussi G,van Dijk R,Collaud F,Charles S,Leborgne C,Vidal P,Martin S,Gjata B,Sola MS,van Wittenberghe L,Vignaud A,Veron P,Bosma PJ,Muro AF,Mingozzi F

    更新日期:2016-07-20 00:00:00

  • Treatment of Hypertensive Heart Disease by Targeting Smad3 Signaling in Mice.

    abstract::Transforming growth factor β (TGF-β)/Smad3 signaling plays a central role in chronic heart disease. Here, we report that targeting Smad3 with a Smad3 inhibitor SIS3 in an established mouse model of hypertension significantly improved cardiac dysfunctions by preserving the left ventricle (LV) ejection fraction (LVEF) a...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.08.003

    authors: Meng J,Qin Y,Chen J,Wei L,Huang XR,Yu X,Lan HY

    更新日期:2020-08-05 00:00:00

  • Treatment of hypophosphatasia by muscle-directed expression of bone-targeted alkaline phosphatase via self-complementary AAV8 vector.

    abstract::Hypophosphatasia (HPP) is an inherited disease caused by genetic mutations in the gene encoding tissue-nonspecific alkaline phosphatase (TNALP). This results in defects in bone and tooth mineralization. We recently demonstrated that TNALP-deficient (Akp2 (-/-) ) mice, which mimic the phenotype of the severe infantile ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2015.59

    authors: Nakamura-Takahashi A,Miyake K,Watanabe A,Hirai Y,Iijima O,Miyake N,Adachi K,Nitahara-Kasahara Y,Kinoshita H,Noguchi T,Abe S,Narisawa S,Millán JL,Shimada T,Okada T

    更新日期:2016-02-03 00:00:00

  • Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors.

    abstract::Adeno-associated virus (AAV) vectors have emerged as a safe and efficient gene therapy platform. One complication is that a significant amount of empty particles have always been generated as impurities during AAV vector production. However, the effects of such particles on AAV vector performance remain unclear. Here ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2016.12.004

    authors: Wang Q,Dong B,Pokiniewski KA,Firrman J,Wu Z,Chin MP,Chen X,Liu L,Xu R,Diao Y,Xiao W

    更新日期:2016-12-24 00:00:00

  • EPPIC (Efficient Purification by Parental Inducer Constraint) Platform for Rapid Generation of Recombinant Vaccinia Viruses.

    abstract::Vaccinia virus (VACV) was successfully used as a vaccine in the smallpox eradication campaign. Since then, it has been widely used in the development of vaccine and therapeutic vectors. However, methods of generating and purifying recombinant VACVs (rVACVs) are often time-consuming, cumbersome, and in some cases requi...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.03.026

    authors: Jasperse B,O'Connell CM,Wang Y,Verardi PH

    更新日期:2020-03-30 00:00:00

  • A qPCR Method for AAV Genome Titer with ddPCR-Level of Accuracy and Precision.

    abstract::Recombinant adeno-associated virus (rAAV) is one of the main vectors used in gene therapy. An accurate genome titer is not only critical for clinical dosing, but also a prerequisite for many analytical assays for AAV product characterization. AAV genome titer is traditionally determined by qPCR; however, assay precisi...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.09.017

    authors: Wang Y,Menon N,Shen S,Feschenko M,Bergelson S

    更新日期:2020-10-01 00:00:00

  • Simple and Fast SEC-Based Protocol to Isolate Human Plasma-Derived Extracellular Vesicles for Transcriptional Research.

    abstract::Extracellular vesicles (EVs) are membranous structures that protect RNAs from damage when circulating in complex biological fluids, such as plasma. RNAs are extremely specific to health and disease, being powerful tools for diagnosis, treatment response monitoring, and development of new therapeutic strategies for sev...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.07.012

    authors: Gaspar LS,Santana MM,Henriques C,Pinto MM,Ribeiro-Rodrigues TM,Girão H,Nobre RJ,Pereira de Almeida L

    更新日期:2020-07-15 00:00:00

  • Partial Reconstruction of the Nigrostriatal Circuit along a Preformed Molecular Guidance Pathway.

    abstract::The overall goal of our research is to establish a preformed molecular guidance pathway to direct the growth of dopaminergic axons from embryonic ventral mesencephalon (VM), tissue placed within the substantia nigra (SN), into the striatum to reconstruct the nigrostriatal pathway in a hemi-Parkinson's disease rat mode...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.06.008

    authors: Ghosh B,Zhang C,Ziemba KS,Fletcher AM,Yurek DM,Smith GM

    更新日期:2019-07-11 00:00:00

  • RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.

    abstract::To date, gene therapy with transiently derived lentivectors has been very successful to cure rare infant genetic diseases. However, transient manufacturing is unfeasible to treat adult malignancies because large vector lots are required. By contrast, stable manufacturing is the best option for high-incidence diseases ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.33

    authors: Marin V,Stornaiuolo A,Piovan C,Corna S,Bossi S,Pema M,Giuliani E,Scavullo C,Zucchelli E,Bordignon C,Rizzardi GP,Bovolenta C

    更新日期:2016-05-11 00:00:00

  • Immunoresponse to Gene-Modified Hematopoietic Stem Cells.

    abstract::Gene transfer to and correction of hematopoietic stem cells (HSCs) are ideal strategies to cure a number of congenital and acquired disorders. However, transgene products may trigger immunological rejection of modified cells, limiting their therapeutic benefits. Preclinical and clinical data indicate that myeloablativ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2019.10.010

    authors: Drysdale CM,Tisdale JF,Uchida N

    更新日期:2019-10-31 00:00:00

  • Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy.

    abstract::Gene therapy has been suggested as a plausible novel approach to achieve seizure control in patients with focal epilepsy that do not adequately respond to pharmacological treatment. We investigated the seizure-suppressant potential of combinatorial neuropeptide Y and Y2 receptor single vector gene therapy based on ade...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.09.004

    authors: Melin E,Nanobashvili A,Avdic U,Gøtzsche CR,Andersson M,Woldbye DPD,Kokaia M

    更新日期:2019-09-18 00:00:00

  • Urocortin 2 Gene Transfer Improves Glycemic Control and Reduces Retinopathy and Mortality in Murine Insulin Deficiency.

    abstract::Type 1 diabetes affects 20 million patients worldwide. Insulin is the primary and commonly the sole therapy for type 1 diabetes. However, only a minority of patients attain the targeted glucose control and reduced adverse events. We tested urocortin 2 gene transfer as single-agent therapy for insulin deficiency using ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.12.002

    authors: Gao MH,Giamouridis D,Lai NC,Guo T,Xia B,Kim YC,Huu VAN,Skowronska-Krawczyk D,Lantier L,Bhargava R,Hammond HK

    更新日期:2019-12-14 00:00:00

  • Human Umbilical Tissue-Derived Cells Secrete Soluble VEGFR1 and Inhibit Choroidal Neovascularization.

    abstract::Exudative age-related macular degeneration (AMD), characterized by choroidal neovascularization (CNV), is the leading cause of irreversible blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs are the standard treatment for AMD, but they have limitations. Cell therapy is a promising a...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.05.007

    authors: Cao J,Yang R,Smith TE,Evans S,McCollum GW,Pomerantz SC,Petley T,Harris IR,Penn JS

    更新日期:2019-05-22 00:00:00

  • Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease.

    abstract::We present an overview of clinical trials involving gene editing using clustered interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), transcription activator-like effector nucleases (TALENs), or zinc finger nucleases (ZFNs) and discuss the underlying mechanisms. In cancer immunotherapy, g...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2020.06.022

    authors: Ernst MPT,Broeders M,Herrero-Hernandez P,Oussoren E,van der Ploeg AT,Pijnappel WWMP

    更新日期:2020-07-03 00:00:00

  • Corrigendum to "Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho-/- mouse".

    abstract::[This corrects the article DOI: 10.1038/mtm.2015.16.]. ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 已发布勘误

    doi:10.1038/mtm.2016.32

    authors: Palfi A,Chadderton N,O'Reilly M,Nagel-Wolfrum K,Wolfrum U,Bennett J,Humphries P,Kenna P,Millington-Ward S,Farrar J

    更新日期:2016-05-25 00:00:00

  • CRISPR Activation Enhances In Vitro Potency of AAV Vectors Driven by Tissue-Specific Promoters.

    abstract::Validation of gene transfer vectors containing tissue-specific promoters in cell-based functional assays poses a formidable challenge for gene therapy product development. Here, we describe a novel approach based on CRISPR/dCas9 transcriptional activation to achieve robust transgene expression from transgene cassettes...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.03.004

    authors: McDougald DS,Duong TT,Palozola KC,Marsh A,Papp TE,Mills JA,Zhou S,Bennett J

    更新日期:2019-03-28 00:00:00

  • The Use of Values WNR and GNR to Distinguish between and Diagnose Different Types of Pancreatitis.

    abstract::There is no effective serologic parameter to distinguish different types of pancreatitis now. To distinguish between acute pancreatitis (AP) and acute exacerbations of chronic pancreatitis (CP) and to determine whether fibrosis occurs in CP, we evaluated the ability to produce white blood cells (WBCs), the neutrophil-...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.05.010

    authors: Luo L,Zhang J,Yang J,Zhang H,Tang Y,Yang D,Dong H,Wu Y,Wang H,Ni B,Tian Z

    更新日期:2020-05-22 00:00:00

  • Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice.

    abstract::New methods to produce large numbers of myeloid progenitor cells, precursors to macrophages (MΦs), by maintaining Hoxb8 transcription factor activity1 has reinvigorated interest in MΦ cell therapies. We generated Hoxb8-dependent myeloid progenitors (HDPs) by transducing lineage-negative bone marrow cells with a consti...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2017.08.007

    authors: Lee S,Kivimäe S,Szoka FC

    更新日期:2017-09-07 00:00:00

  • Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.

    abstract::X-linked severe combined immunodeficiency (SCID-X1) is caused by mutations in the interleukin-2 receptor γ chain gene (IL2RG), and it is characterized by profound defects in T, B, and natural killer (NK) cell functions. Transplantation of hematopoietic stem/progenitor cells (HSPCs) genetically corrected with early mur...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.03.002

    authors: Poletti V,Charrier S,Corre G,Gjata B,Vignaud A,Zhang F,Rothe M,Schambach A,Gaspar HB,Thrasher AJ,Mavilio F

    更新日期:2018-03-10 00:00:00

  • Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy.

    abstract::Retroviral vectors, including those derived from gammaretroviruses and lentiviruses, have found their way into the clinical arena and demonstrated remarkable efficacy for the treatment of immunodeficiencies, leukodystrophies, and globinopathies. Despite these successes, gene therapy unfortunately also has had to face ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2017.10.002

    authors: Biasco L,Rothe M,Büning H,Schambach A

    更新日期:2017-10-05 00:00:00